Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 8/20 | 0.59 |
| ▸ | KDR | P35968 | 8/20 | 0.59 |
| ▸ | JAK3 | P52333 | 7/20 | 0.59 |
| ▸ | MAPK14 | Q16539 | 7/20 | 0.59 |
| ▸ | TEK | Q02763 | 4/20 | 0.59 |
| ▸ | DDR2 | Q16832 | 4/20 | 0.54 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.49 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.49 |
| ▸ | LDHA | P00338 | 1/20 | 0.48 |
| ▸ | LDHB | P07195 | 1/20 | 0.48 |
| ▸ | BRAF | P15056 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.46 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.46 |
| ▸ | CDK1 | P06493 | 1/20 | 0.46 |
| ▸ | CSF1R | P07333 | 1/20 | 0.46 |
| ▸ | PRKACA | P17612 | 1/20 | 0.46 |
| ▸ | FLT1 | P17948 | 1/20 | 0.46 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.46 |
| ▸ | CDK2 | P24941 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21402130 | 1.00 | LCK (0.59) | LCKKDRJAK3MAPK14TEK | |
| SCHEMBL5501169 | 1.00 | LCK (0.59) | LCKKDRJAK3MAPK14TEK | |
| SCHEMBL5497196 | 0.88 | LCK (0.62) | LCKKDRJAK3MAPK14TEK | |
| SCHEMBL13220044 | 0.86 | ROCK2 (0.56) | KDRROCK2ROCK1LDHALDHB | |
| SCHEMBL21402152 | 0.86 | LCK (0.54) | LCKKDRJAK3MAPK14TEK | |
| SCHEMBL14568148 | 0.86 | LCK (0.54) | LCKKDRJAK3MAPK14TEK | |
| SCHEMBL5502111 | 0.86 | LCK (0.54) | LCKKDRJAK3MAPK14TEK | |
| SCHEMBL5504600 | 0.85 | LCK (0.53) | LCKKDRJAK3MAPK14TEK | |
| SCHEMBL21402133 | 0.85 | LCK (0.53) | LCKKDRJAK3MAPK14TEK | |
| SCHEMBL14568052 | 0.85 | LCK (0.53) | LCKKDRJAK3MAPK14TEK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1836174-B2 | ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | AMGEN INC (US) | 2019-10-02 | — | — | EP | claimed |
| EP-1836174-B1 | ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | AMGEN INC (US) | 2013-02-27 | — | — | EP | claimed |
| US-20070054916-A1 | Aryl nitrogen-containing bicyclic compounds and methods of use | AMGEN INC. | 2007-03-08 | — | — | US | claimed |
| EP-1836174-B2 | ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | AMGEN INC (US) | 2019-10-02 | — | — | EP | disclosed |
| EP-1836174-B1 | ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | AMGEN INC (US) | 2013-02-27 | — | — | EP | disclosed |
| US-20070054916-A1 | Aryl nitrogen-containing bicyclic compounds and methods of use | AMGEN INC. | 2007-03-08 | — | — | US | disclosed |
| US-20070054916-A1 | Aryl nitrogen-containing bicyclic compounds and methods of use | AMGEN INC. | 2007-03-08 | — | — | US | disclosed |
| US-20070054916-A1 | Aryl nitrogen-containing bicyclic compounds and methods of use | AMGEN INC. | 2007-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054916-A1 | Aryl nitrogen-containing bicyclic compounds and methods of use | MAP3K1, MAP3K5, MAP3K2 | LCK 106/4885KDR 1044/4885JAK3 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.